New hope for fighting a deadly HIV brain infection
NCT ID NCT00120367
Summary
This study tested if adding a new drug called enfuvirtide (FUZEON®) to standard HIV therapy could better control a rare and severe brain infection called PML in people with HIV. It involved 30 patients in France who received the intensified drug combination for 6 months, followed by 6 more months of standard therapy. The main goal was to see if this approach improved one-year survival rates compared to existing treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service de Medecine interne et Maladies Infectieuses, Hopital Bicetre
Le Kremlin-Bicêtre, 94270, France
Conditions
Explore the condition pages connected to this study.